Jared Kaltwasser | Authors

May 16, 2022

Patients with endometrial cancer who have low volumetric skeletal muscle measurements had lower 3-year overall and progression-free survival rates.

July 02, 2021

Phase 2 data showed just over half of patients given dual therapy had a major pathological response, compared to just 6.7% of those receiving durvalumab monotherapy.

June 18, 2021

The new data may put to rest concerns that adding perioperative systemic therapy might worsen outcomes in patients slated for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

June 02, 2021

Patients who underwent advanced molecular imaging had higher rates of disease-free survival, according to new research.

June 01, 2021

Most elderly patients with acute myeloid leukemia and myelodysplastic syndromes cannot undergo intensive chemotherapy, but more than half of the patients in a new study responded to a regimen of ultra low–dose decitabine and low-dose cytarabine with G-CSF.

May 17, 2021

New data show pain worsened faster, and more dramatically, in patients given placebo versus selinexor for dedifferentiated liposarcoma, as measured by the European Organisation for Research and Treatment of Cancer’s 30-item core quality of life questionnaire.

May 11, 2021

Patients with non–small cell lung cancer and PD-L1 tumor proportion scores of at least 50% had a median 5-year overall survival rate of 26.3%, showing a significant improvement versus standard of care.

May 04, 2021

Adding daratumumab led to at least a very good partial responses in all 41 patients receiving weekly carfilzomib, lenalidomide, and dexamethasone, and complete responses in all but 2 patients.

May 03, 2021

Recent guidelines have advised against routine use of sentinel lymph node biopsy and radiotherapy in patients over age 70 years with breast cancer, but a new study finds most patients still receive the interventions.

April 19, 2021

Patients treated in a multicenter trial experienced a median progression-free survival of 13.2 months with pembrolizumab versus 8.3 months in those receiving brentuximab vedotin.